Accurate International

What Accurate International does

Accurate International (创芯国际), formally Chuangxin International Biotechnology (Guangzhou) Co., Ltd., is a China-based organoid technology platform founded in 2018 and headquartered in Guangzhou's Huangpu District. It operates an "organoid full lifecycle" platform that integrates tumor organoid modeling, disease-model and normal-tissue organoids, drug sensitivity evaluation, identification, immune co-culture, and gene editing, supported by an AI-powered AOD Organoid Big Database. The company is recognized as a National High-Tech Enterprise, Guangdong Province Organoid Engineering Technology Research Center, Guangdong Specialized and Innovative SME, and Guangdong IP Demonstration Enterprise, and holds 100+ patents covering organoid products and services.

The company generates revenue across three streams: (1) clinical testing services under the 蓓芯安® and 蓓芯康® brands, providing individualized organoid drug sensitivity testing — alone or combined with next-generation sequencing — to guide personalized anti-tumor drug selection for cancer patients; (2) new drug R&D services acting as a CRO for pharmaceutical companies, covering drug discovery through post-market evaluation; and (3) smart manufacturing equipment, selling proprietary instruments — Accuauto® automated cell smart laboratories, Auridrop® multi-dimensional immune co-culture workstations, and Accuro-Cult™ rotary CO2 incubators — to global research institutions. Distribution is direct enterprise sales to 200+ core hospitals domestically and to research institutions internationally, with strategic support from joint laboratories at China Pharmaceutical University and Zhuhai Macau University Research Institute, and a medical-supply-chain partnership with Shangpharma.

The company's go-to-market is sales-led, leveraging hospital networks, academic collaborations, industry conferences, and government designations. It has raised approximately RMB 200 million across two disclosed rounds — a RMB 100 million Pre-B led by Daocheng Caizhi in October 2022 and a RMB 100 million Series B led by Guangdong Technology Financial Group in May 2025. Notable commercial and scientific validation includes the world's first expert consensus on organoid drug sensitivity testing in precision oncology, a Cell Reports Medicine publication (IF 16.988) on patient-derived lung cancer organoids with Guangdong Provincial People's Hospital, and a dense cluster of municipal and regional awards in 2025–2026.

Name

Accurate International

Legal name

创芯国际生物科技（广州）有限公司

Website

https://3dbudcare.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Accurate International is a Guangzhou-based organoid technology platform providing clinical drug-sensitivity testing, CRO services for new drug R&D, and proprietary automated lab equipment to hospitals, pharmaceutical companies, and global research institutions.

Ownership category

akta.pro rank

Product category

Organoid biotechnology services and equipment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Organoid technology platform
• Drug sensitivity testing
• Precision medicine services
• Organoid drug discovery
• Automated cell laboratory equipment

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. 临床检测服务 (Clinical Testing Services): Provides organoid-based drug sensitivity testing for cancer patients to guide personalized anti-tumor drug selection. Revenue generated through individual patient testing fees and institutional contracts with hospitals.
2. 新药研发服务 (New Drug R&D Services): Offers full-process evaluation from drug discovery, preclinical research, clinical research to post-market drug studies through organoid technology platform. Serves as a CRO providing contract research services to pharmaceutical companies.
3. 智能制造/产品销售 (Smart Manufacturing Equipment Sales): Sells automated organoid laboratory equipment including Accuauto automated cell smart lab systems, Auridrop immune co-culture workstations, and Accuro-Cult rotary CO2 incubators to global research institutions.
4. 类器官建模与相关技术服务: Provides organoid modeling services for tumor, disease model, and normal tissue organoids, as well as organoid identification, gene editing, and related technical services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Accurate International (Chuangxin International) operates an organoid full lifecycle technology platform delivering three integrated business lines: clinical drug sensitivity testing services for cancer patients via hospitals (蓓芯安® and 蓓芯康®), contract research and preclinical organoid-based evaluation services for pharmaceutical companies (CRO), and proprietary automated organoid laboratory equipment (Accuauto, Auridrop, Accuro-Cult) sold to research institutions, all backed by the AI-powered AOD organoid big database.

Product overview

Accurate International (创芯国际) offers a comprehensive organoid full lifecycle technology platform with three core business segments: (1) Clinical Testing Services featuring 蓓芯安® (organoid drug sensitivity testing) and 蓓芯康® (organoid testing combined with next-generation sequencing); (2) New Drug R&D Services including organoid model platforms and a large organoid database (AOD); and (3) Intelligent Manufacturing products including 奥图优® Accuauto automated cell smart laboratory, 奥智因® Auridrop multi-dimensional immune co-culture workstation, and 奥智衡™ Accuro-Cult rotary CO2 incubator. The company positions itself as a global innovation benchmark in organoid technology, providing high-throughput, high-fidelity solutions for drug discovery, precision medicine, and regenerative medicine.

Differentiator

Problem solved

Functional benefit

Brands

• 奥图优® Accuauto: 全自动细胞智慧实验室 (Fully automated cell smart laboratory)
• 奥智因® Auridrop
• 奥智衡™ Accuro-Cult
• 蓓芯安®
• 蓓芯康®

Products and services

• Accuauto (奥图优®) Fully Automated Cell Smart Laboratory Fully automated cell smart laboratory system for high-throughput, standardized, and digitized organoid production, sold to global research institutions requiring industrialized organoid manufacturing.
• Auridrop (奥智因®) Multi-dimensional Intelligent Organoid Immune Co-culture Workstation Multi-dimensional intelligent connected workstation enabling complex organoid-immune co-culture experiments for immunotherapy research, sold to research institutions globally.
• Accuro-Cult (奥智衡™) Rotary Automated CO2 Incubator Rotary automated CO2 incubator designed for consistent, high-throughput, standardized organoid culture maintenance, sold to research institutions.
• Beixin'an (蓓芯安®) Organoid Individualized Drug Sensitivity Testing Phenotypic organoid-based drug sensitivity testing service that screens anti-tumor drug regimens for individual cancer patients to improve chemotherapy and targeted therapy response rates and reduce drug resistance.
• Beixinkang (蓓芯康®) Organoid Individualized Drug Sensitivity Testing & Next-Generation Sequencing Combined organoid drug sensitivity testing and next-generation sequencing service delivering comprehensive precision medicine analysis for oncology treatment decision support.
• Organoid-based New Drug R&D Services (CRO) Full-process CRO services covering drug discovery, preclinical research, clinical research, and post-market drug studies through the company's organoid technology platform, delivered to pharmaceutical companies.
• Organoid Modeling and Related Technical Services Service offering for tumor organoid, disease model organoid, and normal tissue organoid construction, including organoid identification and gene editing services delivered to researchers and biopharma clients.

Quantifiable outcome

• 32,000+ organoid models generated
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature8 records

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

• 中山大学 - 张力/方文峰团队 (Sun Yat-sen University - Zhang Li & Fang Wenfeng Team)coreStrategic or Co-development Partner · 24 May 2024First disclosure of non-small cell lung cancer patient drug resistance mechanisms using organoid-based molecular typing for precision treatment strategy. Joint research collaboration.
• 国家呼吸医学中心 (National Respiratory Medical Center)coreStrategic or Co-development Partner · 29 April 2024Explored organoid technology advancements with the National Respiratory Medical Center, jointly advancing future respiratory medicine research.
• 上药医疗供应链 (Shangpharma Medical Supply Chain)coreStrategic or Co-development Partner · 10 April 2024Strategic cooperation signed between Shangpharma Medical Supply Chain and 创芯国际 for complementary advantages and innovative collaboration in the medical supply chain.
• 广东省人民医院 - 杨衿记教授团队 (Guangdong Provincial People's Hospital - Professor Yang Jindi Team)flagshipStrategic or Co-development Partner · 19 January 2023Major joint research published in Cell Reports Medicine (IF: 16.988) on using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response. Research funded by Guangdong high-level hospital construction project and national/provincial natural science funds.
• 珠海澳大科技研究院 (Zhuhai Macau University Research Institute)flagshipStrategic or Co-development Partner · 23 September 2022Joint organoid laboratory established in Hengqin Guangdong-Macao Deep Cooperation Zone. Inauguration attended by officials from Guangzhou Science and Technology Bureau, Macau representative offices, and senior leadership from Macau University. Also serves as joint laboratory with Guangdong Organoid Research Center.
• 中国药科大学 (China Pharmaceutical University)flagshipStrategic or Co-development Partner · 27 August 2022Established joint organoid laboratory and signed professional degree graduate school-level practice base agreement. Multiple pharmaceutical company representatives attended the ceremony including Jiangsu Zhengdaqingtian, Nanjing Boshimedia, Nanjing Yaojiekang, Jiangsu Aosaikang, Shenghe Pharmaceutical, and other pharma partners.
• 江苏正大天晴 (Jiangsu Zhengdaqingtian)minorOthers · 27 August 2022Pharmaceutical company representative attending joint laboratory inauguration ceremony with China Pharmaceutical University.
• 圣和药业 (Shenghe Pharmaceutical)minorOthers · 27 August 2022Pharmaceutical company representative attending joint laboratory inauguration ceremony with China Pharmaceutical University.
• 先声药业 (Simcere Pharmaceutical)minorOthers · 27 August 2022Pharmaceutical company representative attending joint laboratory inauguration ceremony with China Pharmaceutical University.
• 中国抗癌协会肿瘤标志专业委员会 (CACA Tumor Marker Professional Committee)flagshipStrategic or Co-development Partner · 10 July 2022Co-published the world's first expert consensus on clinical application of organoid drug sensitivity testing for guiding precision oncology treatment. Published jointly with CACA Tumor Marker Professional Committee, Chinese Journal of Cancer Prevention and Treatment, Guangdong Organoid Engineering Technology Research Center, and Guangdong Precision Medicine Application Society Organoid and Organ Chip Branch.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Xilis: Xilis is a US-based precision oncology company developing patient-derived organoid platforms for drug response prediction and cancer therapy selection. It overlaps with Accurate International's clinical drug sensitivity testing business and competes for pharmaceutical partnerships in the same oncology precision medicine space.
• Emulate: Emulate develops organ-on-chip technology and automated lab systems for drug development and disease modeling. It overlaps with Accurate International's smart manufacturing equipment line (Accuauto, Auridrop) and competes in supplying organoid/organ-chip platforms to global research institutions.
• CN Bio: CN Bio is a UK-based organ-on-chip and microphysiological systems company offering preclinical drug testing platforms. It is comparable to Accurate International in providing advanced in vitro models for pharma R&D, though with a stronger focus on organ-on-chip versus organoid technologies.

Direct peers

• DefiniGEN: DefiniGEN provides iPSC-derived organoid and cell-based disease modeling services for drug discovery and preclinical research. It competes directly with Accurate International in offering organoid-based services to pharma R&D teams, particularly in metabolic and liver disease indications.
• Crown Bioscience: Crown Bioscience is a global preclinical CRO offering patient-derived xenograft (PDX) and organoid services for oncology drug discovery. It is one of the most direct competitors to Accurate International's organoid CRO business, serving the same pharmaceutical customers with overlapping preclinical-to-clinical translational offerings.

Broad incumbents

• Pharmaron: Pharmaron is a global CRO/CDMO offering integrated drug discovery, preclinical, and clinical services from China-anchored facilities. It is a broad incumbent competing with Accurate International for pharmaceutical CRO contracts, though it lacks a dedicated organoid platform.
• WuXi AppTec: WuXi AppTec is the largest Chinese CRO offering preclinical, clinical, and biologics services globally. While not an organoid specialist, its preclinical and clinical CRO offerings overlap with Accurate International's new drug R&D services, and it competes for the same pharmaceutical customer budget allocations in China.
• Tempus AI: Tempus AI is a US precision medicine company combining molecular data, AI, and clinical testing to support oncology treatment decisions. While not an organoid specialist, its AI-enabled precision oncology decision support overlaps thematically with Accurate International's AOD database and AI-drug-response prediction capabilities.

Others

• Hubrecht Organoid Technology: Hubrecht Organoid Technology (HUB) is the foundational organoid technology organization established from the Hans Clevers lab, holding core patents on LGR5+ stem cell organoid technology. It is comparable as the upstream licensor/ecosystem reference for the entire organoid industry in which Accurate International operates.

Regional players

• BeBetter Med: BeBetter Med is a Chinese organoid and precision medicine company developing patient-derived organoid models for clinical drug sensitivity testing and pharmaceutical research. It is the closest domestic Chinese peer to Accurate International, competing in the same hospital-channel and CRO services markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accurate International